Fibromyalgia: review about biomarker and molecular aspect by GIACOMELLI, CAMILLO
  
 
 
 
 
 
Università degli Studi di Pisa 
Tesi di dottorato  
“Fibromyalgia: review about biomarker and 
molecular aspect” 
 
 
  
Dott. Camillo Giacomelli 
Relatore Prof. Antonio Lucacchini 
 
 
 
 
 
 
 
 
 2 
Indices 
Abstact pag.  3 
Fibromyalgia: definition and concepts pag.  4 
Fibromyalgia and Peripheral Benzodiazepine Receptors  pag. 6 
Fibromyalgia and Serotonin Transporter pag. 16 
Thyroid dysfunction in Fibromyalgia pag. 25 
Fibromyalgia and Anti-Polimer Antibodies pag. 34 
ATP, Calcium and Magnesium in Fibromyalgia pag. 41 
Quality of life in Fibromyalgia  pag 52 
Conclusion pag.  58 
References pag. 61 
Acknowledgment pag. 81 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
Abstract 
The fibromyalgia syndrome (FMs) is a non-articular rheumatic condition 
characterized by a variety of symptoms related to pain.  Like many other 
clinical syndromes, FM has no single specific feature but represents a 
complex of symptoms of self reported or clinical deduction. Unfortunately,  
there is still no standardized laboratory test to detect FM or measure its 
severity. The aim of our work was to investigate various biological aspect 
of FM, trying to find biological markers useful to diagnosis and which could 
be used as a pharmacological target. In particular we analyzed the 
pheripharal Benzodiazepina receptor, the alteration of serotonin 
transporter, the concentration of Anti-polymer antibodies, the association 
between thyroid autoimmunity and FM severity, and the ATP, Magnesium 
and calcium levels in platelet of fibromyalgic patients. Moreover, we 
analyzed the psychiatric comorbidity of a cohort of FM subjects, to 
correlate the Quality of life of FM patients and the psychiatric illness.   
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Fibromyalgia: definition and concepts 
Fibromyalgia (FM) is a common form of chronic non-joint rheumatic pain 
wich manifests itself by generalized pain and stiffness of the muscles and 
other soft tissues, as well as the presence of painful tender points 
sensitive to pressure in various characteristic areas.  FM is defined by 
widespread pain for longer than 3 month and by the presence of 11 of 18 
Tender Points (TP) 1,2. 
Most FM patients reports fatigue, disrupted or non-restorative sleep, mood 
disturbances, exercise induced symptom flares and multiple other 
syndromes (e.g., restless leg syndrome, irritable bowel syndrome and 
chronic headaches) 3,4. Physical and emotional health as well as quality of 
life is often seriously impaired 5.  
FM has a different prevalence depending on the population studied and 
the criteria used, oscillating from 0.7% to 20%6. Most FM patients are 
middle-aged women (73-88%). However it has also been described in 
children7, as well as in the elderly8. In a rheumatology unit, about 10-20% 
of the patients suffer FM, a proportion that descends to 2.1-5.7% in non-
specialized clinics6-9.  In a large cohort of Spanish patients the prevalence 
of FM in the adult population is estimated at 2.37% (95% CI: 1.53-3.21)10. 
80 to 90% of fibromyalgia suffers are women. Like many other clinical 
syndromes, FM has no single specific feature but represents a complex of 
symptoms of self reported or clinical deduction. Unfortunately,  there is still 
no standardized laboratory test to detect FM or measure its severity. The 
aim of our work was to investigate various biological aspect of FM, trying 
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to find biological markers useful to diagnosis and which could be used as 
a pharmacological target. In particular we analyzed the pheripharal 
Benzodiazepina receptor11, the alteration of serotonin transporter12, the 
concentration of Anti-polymer antibodies 13 , the association between 
thyroid autoimmunity and FM severity14, and the ATP, Magnesium and 
calcium levels in platelet of fibromyalgic patients15. Moreover, we analyzed 
the psychiatric comorbidity of a cohort of FM subjects, to correlate the 
Quality of life of FM patients and the psychiatric illness.   
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Fibromyalgia and Peripheral Benzodiazepine Receptors 
In addition to binding of GABAA receptors in the central nervous system, 
benzodiazepines bind to other sites in peripheral tissues. This second type 
of recognition sites is termed peripheral type benzodiazepine receptor 
(PBR) 16. PBR is a protein enriched in the mitochondrial outer membrane 
with widespread expression through-out the body, particularly in 
steroidogenic tissues 17,18 and in various types of human blood cells 19. In 
the nervous system, PBR has been identified in the choroids plexus, the 
ependymal linings, astrocytes and microglia 20,21. 
The diazepam binding inhibitor, a 10 kDa polypeptide found within brain 
and other regions of the body, along with porphyrin, have been proposed 
to be endogenous ligands for the PBR22 , 23 . Several pharmacological 
ligands also bind to the receptor and elicit a wide range of effects 24,25,26,27. 
Although extensively characterized pharmacologically and 
biochemically, and implicated in numerous biological processes, the 
precise function of the PBR is unknown. More direct studies of PBR 
function have yielded a diverse list of activities involving the PBR, 
including the regulation of cellular proliferation 28, immunomodulation29, 
porphyrin transport, and heme biosynthesis 30 , steroidogenesis 31 , and 
apoptosis32. One line of evidence suggests that the PBR plays a major 
role in the regulation of immune function. PBR ligand have been found to 
modulate cellular functions such as chemotaxis33 , respiratory burst34 , and 
cytokine secretion35, 36. 
 7 
Treatment of mice with Ro5-4864 markedly reduces the capacity of 
macrophages to produce key mediators of inflammation such as 
superoxide anion, interleukin-1 (IL-1), tumor necrosis factor α (TNF-α), 
and interleukin-6 (IL-6)37 . PBR activating ligands have anti-inflammatory 
and antinociceptive effects38,39,40,41,42. 
These data, together with the immunomodulatory studies indicating that 
PK11195 and Ro5-4864 can regulate inflammatory responses 43 , 
suggested that specific PBR ligand might be potential anti-inflammatory 
agents26,32. 
Interestingly, changes in PBR levels have been linked to the 
hypothalamo-pituitary-adrenal system (HPA)44. Moreover, PBR density is 
modulated under a variety of physiological or pathologic conditions. 
Several pathologic states including stress 45 , Alzheimer’s disease 46 , 
trauma47, mitochondrial diseases48, and rheumatic diseases49,50 are also 
associated with changes in PBR expression. 
Based on these consideration and to evaluate whether PBR 
involvement occurs in FM, as indicated by cytometry with indirect 
immunofluorescence in monocytes of FM patients51, we chose platelets for 
our binding studies because of our interest for mitochondria, the principal 
source of cell energy; moreover platelets are not nucleated, so they 
represent a simple and stable model in which there are no nuclear 
interference phenomena. Thus, the objective of this study was to evaluate 
the alterations of PBR characteristics that occurred in platelets of patients 
affected by FM compared with healthy controls. 
 8 
For this study we enrolled Thirty consecutive patients affected by primary 
FM (30 all females), aged 53.3 ± 12 years (mean ± SD) and 16 healthy 
controls with characteristics of sex and age comparable with the FM 
patients, took part in the study. FMS diagnosis is usually established by 
criteria according to the American College of Rheumatology2. Prior to 
inclusion in the study, to exclude any psychiatric disorder, all the subjects 
were evaluated by means of a structured psychiatric interview. Included 
subjects had to be free of comorbid psychiatric disorder as defined in the 
Diagnostic and Statistical Manual of Mental Disorder, fourth edition 52  . 
None of the subjects had or a negative history for psychoactive drug 
treatment and other neurological disorders and not received treatment with 
antidepressant drugs. No patient was under pharmacological treatment. 
Depressive symptoms were scored using the Beck Depression Inventory 
(BDI) in all patients and controls. Patients with the FM were divided into 
two groups for high or low BDI score according to whether the BDI score 
was ≥ 17 or < 17, respectively.  
For each patient and control the tenderness at tender points (TP) were 
evaluated by means of the Fischer dolorimeter53 [48]. Each positive TP had 
a pain score between 0 and 3. 
To estimate the impact of fibromyalgia on the quality of life, all the 
patients received a “Fibromyalgia Impact Questionnaire” (FIQ) consisting of 
10 items, from which derived a score that indicates the impact of the 
disease on life (FIQ total score)54. The total score reflected the impact of 
fibromyalgia and ranged from 0 (no impact) to 100 (maximum impact). 
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The patients filled out a questionnaire to assess the presence or 
absence of stiffness, paresthesia, lumbosciatalgy, non-restorative sleep, 
anxiety-depression, cramp, xerostomia, tension headache, irritable bowel, 
temporomandibular dysfunction symptoms, xerophtalmy, vertigines, 
gastroesophageal reflux disease, restless leg syndrome, Raynaud 
phenomenon, hyperaesthesia, allergy, post traumatic stress disorder, 
hematologic alterations. The questionnaire also let us know the onset of 
FM symptoms. 
Laboratory variables included erythrocyte sedimentation rate (ESR), 
level of C-reactive protein (CRP) and other aspecific markers of 
inflammation. IL-1, IL-6, IL-8, IL-10 and TNF-α were quantified by means of 
enzyme-linked immunosorbent assay (ELISA) methods (Pantec) in plasma 
diluted 1 : 2 based on appropriate and validated sets of monoclonal 
antibodies. Cortisol levels were measured by immunologic method with 
fluorescence polarized light in sera. 
Preparation of platelet membrane and [3H] PK11195 binding assay were 
performed as previously described38.  
Baseline characteristics of patients with FM and healthy controls are 
presented in table 1. 
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Table 1. Characteristics of FM patients and healthy controls. 
Variables 
Fibromyalgia 
(n= 30) 
Controls 
(n= 16) 
Age (years) 53.3 ± 12 51.5 ± 10 
FIQ 56.6 ± 3.5 20.7 ± 2.3 
TP  14.4 ± 4 0.6 ± 0.2 
Pain  6.8 ± 0.6 2.5 ± 0.5 
Tiredness 7.2 ± 0.5 2.8 ± 0.4 
 
Results are shown as mean (± S.D.). FIQ, Fibromyalgia Impact Questionnaire; TP, 
Tender Points. 
 
In our study, BDI scores in group of patients was significantly higher than 
those of the control subjects (*p< 0.05); moreover, high BDI scores (≥ 17), 
indicating depression, were detected in 53.3% of patients with FM (table 
2). All patients with FM have CRP < 4 mg/l and ESR < 35 mm/h (data not 
shown). There were no significant difference in levels of IL-1, Il-6 IL-10 
and TNFα (data not shown), whereas IL-8 levels were significantly higher 
only in FM patients with high BDI scores than in healthy controls (*p < 
0.05) (table 2). Cortisol levels were significant lower in FM patients (*p < 
0.05), in particular, among the FM patients, cortisol levels were 
significantly lower in those with high BDI scores than in controls (*p < 
0.05), but there was no significant difference between those with low BDI 
scores and controls. There was no significant difference between FM 
patients with and those without depressive symptoms. 
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Table 2: Cortisol and IL-8 levels and scores of BDI inj patients and healthy control 
subjects 
Variables 
All FM 
(n = 30) 
FM 
BDI < 17 
(n = 14) 
FM 
BDI ≥ 17 
(n = 16) 
Controls 
(n = 16) 
Age (years)  53.3 ± 12 50.5 ± 12 55.8 ± 12 51.5 ± 10 
IL-8 (pg/ml) 35.5 ± 22.2 31.0 ± 22.0 39.3 ± 22.0* 19.6 ± 4.9 
Cortisol (pg/ml) 11.54 ± 5.2* 12.24 ± 4.8 10.93 ± 5.6* 16.5 ± 6.5 
Results are shown as mean (± S.D.). *Significantly different from control value (p < 0.05). 
 
 
For each platelet membrane sample, obtained from patients and 
healthy volunteer, [3H] PK11195 high-affinity binding sites were detected. 
Table 3 summarizes the mean values of [3H] PK11195 binding parameters 
(Bmax and Kd) in patients and controls. No significant differences were 
found as regards the Kd values (mean ± SEM) between the control group 
(4.74 ± 0.39 nM) and the patients (4.90 ± 0.39 nM). On the contrary, Bmax 
values (mean ± SEM) were significantly higher in FM patients (5366 ± 188 
fmol/mg protein) with respect to the healthy volunteers (4193 ± 341 
fmol/mg protein) (**p < 0.01). In particular, Bmax values were more 
significantly higher in those with high BDI score than in controls (***p < 
0.001), but no difference statistically significant were found between those 
with low BDI score and controls.  
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Table 3. [3H]PK11195 binding parameters (Bmax and Kd) on platelet membranes of 
normal and patients with fibromyalgia. 
Variables 
All FM 
(n = 30) 
FM 
BDI < 17 
(n = 14) 
FM 
BDI ≥ 17 
(n = 16) 
Controls 
(n = 16) 
Bmax (fmol/mg)  5366 ± 188** 4928 ± 167 5749 ± 294*** 4193 ± 341 
Kd (nM) 4.9 ± 0.39 4.47 ± 0.49 5.2 ± 0.54 4.74 ± 0.39 
Results are shown as mean (± S.E.M.). **Significantly different from control value 
(p<0.01). ***Significantly different from control value (p<0.001) 
 
The individual Bmax values obtained in patients and controls are shown in 
the scattergrams reported in Fig. 1. 
 
All FM BDI <17 BDI >17 control0
2500
5000
7500
10000
12500
15000
**p<0.01 ***p<0.001
BB BB m
axma
x
ma
x
ma
x (
fm
ol/
mg
 pr
ote
in )
 
fm
ol/
mg
 pr
ote
in
 
fm
ol/
mg
 pr
ote
in
 
fm
ol/
mg
 pr
ote
in
 
Fig 1. Scattergram of individual Bmax values of [3H]PK11195 binding to platelet 
membranes from controls and FM patients. 
Each point represents and individual subject. Bmax values were obtained by Scatchard 
analysis of saturation isotherm. 
 
Correlation between the increase of platelet PBR Bmax and symptom 
scores for patients with BDI ≥ 17 reached a significant level for tiredness 
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(*p < 0.05; r = 0.56) and for pain (*p < 0.05; r = 0.54) (data not shown). By 
contrast, no significant correlation was found for patients with low BDI 
score or Kd values. 
This is the first report of a modification in the binding of [3H]PK11195, a 
specific ligand for PBR, on the platelet membranes of a group of female 
affected by FM. The increase in Bmax recorded was quite marked 27% in 
the entire sampling, all FM patients. Moreover, the increase was grater in 
patients with BDI ≥ 17 (37%) respect to the patients with BDI < 17 (17%). 
In our study we also found significant alterations of other parameters 
suspected to play a role in FM such as a IL-8 and cortisol. Plasmatic 
values of IL-8, a proinflammatory chemokine which promotes sympathetic 
pain, were significantly increased of 100% in FM patients than in controls, 
but only in patients with BDI ≥ 17, according to Wallace et al.,55. Moreover, 
was recorded a decrease of cortisol serum levels, which is the most 
important hormone of the HPA axis, corresponding at 30.1% and 33.8%, 
respectively, in all FM patients and in patients with BDI ≥ 17, in agreement 
with findings of Gur et al56. 
Thus, the changes in number of binding sites of PBR demonstrated in 
our study occurs in a cohort of FM patients having also other interesting 
alterations of substances that may play a role in modulating FM 
symptoms45,46. Moreover, we could observe a significant positive 
correlation between the altered profile of platelet PBR and symptom 
severity such as pain and tiredness scores when we compared this 
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symptoms with Bmax values of patients with high BDI (≥ 17), but not of 
those with low BDI score. 
It is well known that abnormal PBR density frequently occurs in 
pathologic conditions, including neurometabolic or neurodegenerative 
disorder 57 . Moreover, stress has been demonstrated to affect PBR 
bidirectionally. Several studies have shown that PBR density is up-
regulated during acute stress and down-regulated in chronic stress 
conditions. These data have suggested that PBR density changes are 
highly associated with stress, and because FM is often viewed as a stress 
related disorder, as demonstrated by the anomalies of the HPA axis found 
in FM58 , our data may reflects a non adaptive mechanism in FM patients 
to the chronic stress condition of this disease. 
Our data are also in agreement with the greater expression of PBR 
evaluated by cytometry with indirect immunofluorescence in monocytes of 
FM patients41  where the monocyte PBR over increase may be due to 
anomalies in the regulation of pain or to inflammation. Thus we think that 
PBR may be involved mechanistically in the etiopathogenesis of FM as 
suggested by the correlations with pain-related clinical parameters that we 
have found. 
Furthermore, it might be hypothesized that in our FM patients the 
increase of PBR binding sites is involved in steroidogenesis although our 
data showed a decrease rather than a increase in serum cortisol 
concentration occurs. The serum cortisol inadequately low may be due to 
a increased cortisol elimination, characteristic of the premenopausal 
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women 59 , that would lead to relatively low cortisol availability in our 
patients, aged 53.3 ± 12, rather than to alterations in cortisol synthesis and 
release. Therefore, the synthesis it could quite increased as suggested by 
the over expression of PBR that it represents the rate limiting step for the 
synthesis of neurosteroids60. 
In conclusion, our binding data suggest that an up-regulation of PBR 
occur in platelets of FM patients and may provide new insights into the 
pathogenesis of FM and form the basis of future studies on 
steroidogenetic involvement of PBR pain-related in this syndrome. 
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Fibromyalgia and Serotonin Transporter 
FM is often associated with increased prevalence of depressive 
symptoms, major depression and anxiety53. However, there has been a 
growing interest in a possible involvement of serotonin (5-HT) in the FM. 
Indeed, strong evidence has accumulated to support the hypothesis that a 
deficiency in serotonergic neuronal functioning may be related to the 
pathophysiology of FM 61 , 62 , 63 . FM patients have been found to have 
decreased serotonin and tryptophan (serotonin precursor) serum and 
cerebrospinal fluid concentrations. Serotonin, in particular, is theorized to 
play a role in stage 4 sleep and pain threshold64. This neurotransmitter is 
implicated in psychiatric disorders such as depression, anxiety, and 
obsessive compulsive disorder. Stressful experiences lead  to depression 
in some people who already have the genetic predisposition and increase 
the probability of  FM  exordium. The 5-HT gene could moderate the 
serotonergic response to stress 65. 
As a mediator, 5-HT exerts its actions by means of interaction with 
distinct receptors, which are differentiated on the basis of structures, 
molecular mechanisms, and pharmacological profiles59. On this basis, 
drugs acting on 5-HT receptors, in particular on 5-HT2 and 5-HT3, are 
being used or investigated for clinical management of FM66,67. Among 
drugs targeting 5-HT receptors, ketanserin is a selective 5-HT2 antagonist 
which can reduce the hyperalgesia, spontaneous pain, sleep disorders 
and other symptoms of fibromyalgia68; while granisetron and tropisetron 
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are selective 5-HT3 receptor antagonists which show clinical efficacy in 
fibromyalgia62. 
Analogous to other transmitters, the endogenous activity of 5-HT is 
controlled by a specific 5-HT transporter (SERT), which mediates the 
intracellular reuptake of 5-HT and can be specifically blocked by selective 
5-HT reuptake inhibitors (SSRIs), such as paroxetine and fluoxetine. 
SERT is widely expressed in intestinal epithelial cells, central or peripheral 
serotonergic neurons, and platelets, where it shares common molecular 
and physiological feature 69 . Clinical studies have demonstrated the 
efficacy of SSRI in FM70 , but the data are not unequivocal. Nociception 
refers to the physiology process of transmitting painful stimulus from the 
periphery, through afferent neurons to the cerebral cortex. It has been 
postulated that serotonergic neurotransmission plays a significant role in 
nociception71, therefore possible alterations in serotonin metabolism and 
transmission play an important role in the pathogenesis of FM. These 
findings support the proposed hypothesis of aberrant pain perception in 
FM resulting also from an instability of the serotonin system in FM. There 
is also evidence suggesting that changes in the expression of SERT are 
due to a polymorphism in the transcription region in FM patients72. 
In the present study, both expression and functionality of SERT were 
determined in platelets collected from FM patients, for the following 
reasons: 1) to perform a comparison with the pharmacologic profile of 
platelet SERT in healthy volunteers and 2) to examine putative 
correlations of SERT characteristics with severity of symptoms such as 
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tiredness, “Fibromyalgia Impact Questionnaire” (FIQ) score or tender point 
index (TPi). 
For this study we enrolled forty patients affected by primary 
fibromyalgia (all female), aged 53 ± 13 yr (mean ± S.D.) and thirty-eight 
healthy individuals, who did not differ from the patients in age (50 ± 12 
yr)or sex (all female), were used as a control group. The American College 
of Rheumatology (ACR) criteria for fibromyalgia2 were used to make the 
diagnosis of fibromyalgia. The inclusion criteria for the study groups 
comprised a negative history for psychoactive drug treatment and other 
neurological disorders. None of the subjects had comorbid psychiatric 
disorders or received treatment with antidepressant drugs. No patient was 
under pharmacological treatment. All patients underwent a wash-out 
period of 2 months, before the study.  For each patient and control, 
tenderness at tender points was evaluated by means of the Fischer 
dolorimeter48. The total fibromyalgic tender point score (right + left) was 
used in the statistical analysis. Each positive tender point (TP) had a pain 
score between 0 and 3. We also calculated the TPi, as the sum of each 
positive score of TP divided by the total of TP. To estimate the impact of 
fibromyalgia on the quality of life, all the patients and controls received a 
the FIQ questionnaire49.  The characteristic of patients and controls are 
showed in table 4. To exclude major psychiatric disorders, all the patients 
were evaluated by means of a diagnostic interview that consisted of the 
administration of the Structured Clinical Interview for DSM-IV axis-I 
disorder (SCID-I/P)73. This assessment was conducted by psychiatrists 
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who were trained and certified in the use of the study instruments at our 
Department.  
 
Table 4. characteristics of normal subjects and patients with fibromyalgia 
 healthy 
controls 
(mean±SD) 
FM 
patients 
(mean ± 
SD) 
Ref Range 
Age (yr) 50±12 53±13 / 
Gender  F F / 
TPs 2±0,5 14,3±3,72 0-18 
iTP 1±0,5 2,2±0,5 0-3 
FIQ 22,3±16,33 57,1±21,3 0-100 
Tiredness 2,73±2,7 7,4±2,2 0-10 
 
 
[3H]paroxetine binding sites on the SERT of platelet membranes were 
used as a first marker of serotonergic function. Table 5 shows the mean 
Bmax values for the density and Kd for the affinity of [3H]paroxetine binding 
on platelets in the patients and in the healthy controls.  
 
 
 
Table 5. [3H]paroxetine binding characteristics in platelet membranes of normal subjects 
and patients with fibromyalgia 
Variables 
Fibromyalgia  
(n = 30) 
Controls 
(n = 38) 
Bmax (fmol/mg)  1048±30*** 1260 ± 34 
Kd (nM) 0.086 ± 0.021 0.077 ±0.012  
Results are shown as mean (± S.E.M.). Bmax [3H]paroxetine is expressed in fmol/mg of proteins and Kd in nM. 
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A statistically significant difference was found between the two groups 
for Bmax (1048 ± 30 fmol/mg vs. control, 1260 ± 34 fmol/mg, mean ± SEM) 
(***p < 0.0001) but not for Kd (0.086 ± 0.021 nM vs. control, 0.077 ± 0.012 
nM, mean ± S.E.M.). The evaluation of symptom severity in FM patients 
yielded score values ranging from 2 to 10 with a mean value of 7.4 ± 2.2 
(mean ± S.D.) for tiredness, from 1 to 3 with a mean value of 2.2 ± 0.5 
(mean ± S.D.) for TPi, and from 8 to 94 with a mean value of 57.1 ± 21.3 
(mean ± S.D.) for FIQ (Table 2). The severity of symptoms was shown to 
be related to the maximal binding capacity of platelet SERT, inasmuch as 
the statistical analysis showed a negative correlation between symptom 
scores and the respective Bmax values (***p < 0.0001 for tiredness; ***p < 
0.0001 for TPi and ***p < 0.0001 for FIQ). By contrast, no significant 
correlation was found when comparing symptom severity with Kd values. 
Age did not seem to influence the binding parameters of platelet SERT in 
either FM patients or healthy volunteers. [3H]serotonin uptake on platelet 
was used as marker of the functionality of SERT. Mean ± S.E.M. Vmax and 
Km values of [3H]serotonin uptake in FM patients accounted for 90 ± 4 
pmol/109plt/min and 96 ± 15 nM, respectively (Table 6). A comparison of 
these parameters with those in healthy volunteers indicated significant 
differences only for Vmax values, but not for Km values: the mean Vmax 
value in the FM patients was significantly lower (90 ± 4 pmol/109plt/min, vs 
controls, 114 ± 6 pmol/109plt/min) (**p < 0.001), the mean Km value in the 
FM patients was not significantly different (96 ± 15 nM, vs controls, 114 ± 
15 nM) (Table 6). The severity of the symptoms was shown to be related 
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to the Vmax and Michaelis constant, inasmuch as the statistical analysis 
showed a negative correlation between the symptoms scores and the 
respective Vmax values (***p < 0.0001 for tiredness; *p < 0.05 for TPi and 
**p < 0.001 for FIQ). We also found a positive correlation between Km 
values and tiredness (**p < 0.001), TPi (**p < 0.001) and FIQ (**p < 0.001).  
 
Table 6. [3H]5-HT uptake characteristics in platelets of normal subjects and patients with 
fibromyalgia 
Variables Controls (n= 38) Fibromyalgia (n= 40) 
Vmax  114 ± 6 90 ± 4** 
Km 114 ± 15 96 ± 15 
Results are shown as mean (± S.E.M.). Vmax [3H]5-HT is expressed in pmol/109plt/min and Km in nM. 
 
The present study is the first examination of the relationships between 
SERT expression and kinetic parameters of 5-HT uptake. We have found 
statistically significant differences between FM patients and controls in 
Bmax values and Vmax values. Moreover, we have found a negative 
correlation between symptom scores and the respective Bmax and Vmax 
values (Bmax and Vmax vs tiredness, TPi and FIQ score). The platelet is 
considered to be a peripheral model of neuronal activity with respect to 5-
HT function. In fact, previous studies have demonstrated that the same 
SERT is expressed in the central nervous system and platelets 74 . 
Moreover, the identity between the two structures, as confirmed by 
sequence homologies through cloning studies64,  have provoked a surge 
of different studies in neuropsychiatric disorders, given the possibility of 
exploring peripherally a central nervous system mechanism75. Recently it 
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has been proposed that altered serotonergic neuronal function may be 
related to the pathophysiology of FM76. These findings prompted us to 
investigate the characteristics of SERT in the platelets of FM patients. Bmax 
and Kd values of [3H]paroxetine binding were assumed as estimates of 
SERT density and ligand binding affinity, respectively, while Vmax and Km 
values of [3H]5-HT uptake were assumed as estimates of SERT rate and 
affinity, respectively. A very interesting observation was that both binding 
and uptake parameters differed significantly from those evaluated in 
healthy volunteers.  
The FM patients have fewer SERT expressed on the cellular membrane 
than healthy subjects (decreased Bmax, perhaps because the SERT are 
less transcribed). Besides having fewer SERT, FM patients have a deficit 
in functionality (which is evidenced by a decrease in transport rate). Such 
combined changes in Bmax and Vmax values allow the inference that the 
efficiency of 5-HT uptake by platelet SERT is altered. Our previous studies 
evidenced an alteration of SERT density and  of the uptake rate of SERT 
in psychiatric patients77.  
Consistent with this suggestion, in the present study the correlation 
analysis showed that the lower the density and rate of SERT on platelet 
membranes, the higher the severity of FM symptoms. Moreover, the Km 
values also positively correlated with tiredness, TPi and FIQ. 
A reduced density and rate of SERT is consistent with previous 
observations which indicate that the levels of 5-HT are altered in the FM 
patients78. The biophysiological mechanism in FM was proposed to be 
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similar to that in depression, and suggested that this was likely to result 
from a neuroendocrine/neurotransmitter dysregulation 79 . However we 
suppose that the alteration Bmax and Vmax values are not related to the 
pathophysiology of FM but are a conseguence of FM80. It was shown that 
the decreased pain perception threshold during depression is likely to 
result from a dysfunction in several neurotransmitter systems, especially 
the serotoninergic one, which is also involved in the pathophysiology of 
depression 81 . In addition, an excessive stimulation of peripheral 5-HT 
receptors would account for pain and might explain why the clinical use of 
5-HT3 receptor antagonists such as tropisetron or granisetron can promote 
the relief of disturbance associated with FM82. 
SERT has been investigated previously in FM patients, with discordant 
results. Russell83 found a higher Bmax in patients with fibromyalgia than in 
healthy controls, whereas, other authors found normal Bmax values, using  
[3H]paroxetine or [3H]imipramine 84 . In our experiments we used 
[3H]paroxetine which binds with a high affinity to a specific population of 
binding sites located on human platelets and neuronal membranes, 
associated with 5-HT uptake mechanisms85. The present results indicate a 
decrease in the density and rate of platelet SERT in FM patients, and 
allow us to hypothesize a specific role for SERT in the pathogenesis of FM. 
In fact, we avoided the inclusion of FM patients with psychiatric 
components because it is known that in psychiatric disorders such as 
depression, the SERT expression is altered86  and it is very difficult to 
identify the role of the two components in FM patients with comorbid 
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psychiatric disorders. Thus, the changes in the number of binding sites 
and rate of uptake demonstrated in our study may be due to FM only.  
There is also a possible contribution from 5-HT to the aetiology of FM 
because of the efficacy of Serotonin Selective Re-uptake Inhibitors 
(SSRIs) in the management of chronic pain in idiopathic pain disorders87. 
Thus, in view of the decreased Bmax and Vmax values found in our mentally 
healthy subset patients, who were SSRI free, we hypothesize that in CNS 
there is a compensatory mechanism to relieve the pain. This may clarify 
the improvement in SSRI therapeutic effectiveness in the FM patients. 
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Thyroid dysfunction in Fibromyalgia  
Fibromyalgia (FM)-like symptoms such as muscle pain and tenderness, 
exhaustion, reduced exercise capacity, and cold intolerance, resemble 
symptoms associated with endocrine dysfunction, such as adrenal or 
growth hormone insufficiency and hypothyroidism. It was observed that 
different sets of symptoms, diagnosed as different disorders (chronic 
fatigue, immune dysfunction syndrome, post traumatic stress disorder, 
bipolar affective disorder, myofascial pain syndrome, systemic candidiasis, 
breast implant silicone sensitivity syndrome) have a common underlying 
mechanism — an abnormally slow metabolism (called "hypometabolism") 
caused by one or more of the metabolism-impairing factors. Almost all of 
the hormonal feedback mechanisms controlled by the hypothalamus are 
altered in FM88,89,90.  
Evidence exists that most cases of FM are associated with difficulties in 
thyroid production91 or utilization92 and previous authors have documented 
a similar appearance of FM and hypothyroidism93. After stimulation, both 
pituitary and thyroid gland response are less acute in patients with FM; as 
a result, their bodies produced significantly less thyroid-stimulating-
hormone and thyroid hormones than healthy controls. However, the 
relationship between FM and thyroid dysfunction is still unclear, and the 
beneficial effects of T3 administration to hypothyroid patients are still the 
object of debate94,95. 
One cross-sectional study found that the prevalence of thyroid microsomal 
antibodies was significantly higher in people suffering from long-term 
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musculoskeletal complaints throughout the body and evidence exists of an 
association between thyroid autoimmunity and FM 96 . Although the 
mechanism is not known, it has been suggested that the presence of 
muscle symptoms in euthyroid subjects with chronic autoimmune 
thyroiditis might be associated with pre-subclinical hypothyroidism97. 
The aims of our research were: to clinically characterize a cohort of 120 
FM patients by means of clinical investigations (rheumatological and 
psychiatric evaluations), to evaluate thyroid autoimmunity and to 
investigate the relationships between clinical data and symptoms. 
Diagnosis of FM was established by criteria according to the American 
College of Rheumatology (ACR)2 ,  A psychiatric evaluation was made by 
means of a diagnostic interview conducted by psychiatrists at the 
Department of Psychiatry of the University of Pisa. For each patients and 
controls we evaluated TP48, TPi, and FIQ49. Each patient was asked if they 
had frequently suffered from any of the following symptoms in the past 12 
months: fatigue, non-restful sleep, anxiety, depression, irritable bowel 
syndrome, constipation, diarrhea, fingers turning blue/white with cold 
(Raynaud’s phenomenon), paresthesiae (tingling in arms/legs), articular 
stiffness, muscular stiffness, dry eyes, dry mouth, temporomandibular 
disorders (TMD), muscle spasms, tension headache, allergy, low back 
pain, restless leg syndrome, gastroesophageal reflux disease, 
burning/pain with urination, dizziness, allodynia, traumatic event, blurred 
vision and sore throat. The psychiatric evaluation was based on the 
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administration of the Structured Clinical Interview for DSM-IV axis-I 
disorders (SCID-I/P)68.  
Thyroid function was assessed by determining free T3 (fT3), free T4 
(fT4) and thyroid stimulating hormone (TSH). Thyroid autoimmunity was 
evaluated by determination off Antithyroglobulin (TgAb) and antithyroid 
peroxidase (TPOAb). Moreover the following analyses were also 
performed: the aspecific markers of inflammation erythrocyte 
sedimentation rate (ESR) and C reactive protein (CRP). 
The demographic data and clinical characteristics of the patients and 
controls are shown in Table 7. The basal thyroid hormone levels of FM 
patients were found to be in the normal range (Tab.7), but TPOAb and 
TgAb were positive in 31% and 25.6% of the patients, respectively. Forty-
one per cent of the patients had at least one thyroid antibody (in the 
control group, 15% had at least one thyroid antibody). TPOAb levels had a 
positive correlation with TgAb (r=0.49, P=0.0001). 
The psychiatric evaluation of FM patients gave the following results: 50% 
of the patients had a depressive disorder, 30% had anxiety disorders 
(obsessive compulsive, generalized anxiety and panic disorders) and 20% 
had no psychiatric illness. There were no differences as regards age, 
disease duration, FIQ, TP or VAS, and the presence of depression or 
anxiety disorders among the patients were separated according to thyroid 
autoimmunity. Also, the aspecific markers of inflammation were found to 
be in the normal range.   
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Tab. 7. Demographic data, clinical characteristics of the FM patients. Results are 
expressed as mean (SD) or percentage. 
Variables FM (n=120) 
Patients with 
thyroid 
autoantibodies 
(n=49) 
Patients without 
thyroid 
autoantibodies 
(n=71) 
Controls 
(n=30) 
Age (yr) 
range 
50.64 (12.42) 
18-75 52.76 (12.42) 49.56 (12.06) 48.6 (11.18) 
FM duration (yr) 9.59 (8.13) 9.73 (9.41) 9.42 (6.71) - 
Gender 115 F, 5M 48 F, 1 M 67 F, 4M 26 F, 4 M 
FIQ 
Range 
56.12 (19.22) 
10.0 – 98.5 
55.30 (18.52) 55.26 (20.26) - 
T.P. 
range 
13.64 (4.90) 
0 – 18 
13.91 (5.14) 13.46 (4.69) - 
TPi 
Range 
2.16 (0.59) 
0 -3 
2.09 (0.67) 2.19 (0.53) - 
VAS 6.71 (2.47) 6.59 (2.79) 6.73 (2.16) - 
Postmenopausal 
(%) 49.6 55.3 42.4 39 
Depression (%) 47.8 48.1 44.7 - 
Anxiety 
disorders (%) 29.0 29.6 26.3 - 
No psich 
disease 23.19 22.2 21.0 - 
TPOAb (%) 31 - - 10 
TgAb (%) 25.6 - - 15 
Presence of at 
least one thyroid 
antibody (%) 
41 - - 15 
Both thyroid Ab 
(+) (%) 14.7 - - 10 
fT3 mean (SD) 3.61 (1.46) 3.38 (1.05) 3.59 (1.38) 3.71 (0.26) 
fT4 11.68 (3.57) 11.59 (2.78) 11.89 (3.87) 12.98 (1.23) 
TSH 1.68 (0.95) 1.67 (0.94) 1.68 (1.02) 1.39 (0.82) 
CRP 0.49 (0.43) 0.53 (0.55) 0.46 (0.32) * 
ESR 14.44 (12.06) 14.46 (10.65) 13.98 (13.12) * 
  
 
In table 8 we reports the clinical characteristics of patients separated 
according to the presence/absence of thyroid autoantibodies. Patients with 
thyroid autoimmunity showed a higher percentage of dry eyes (56% vs 
36.5%, p<0.05), burning/pain with urination (36.0 vs 10.0 %, P<0.01), 
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allodynia (73.5 vs 32.4 %, P<0.01), blurred vision (48.9 vs 22.5, P<0.01) 
and sore throat (43.7 vs 16.9 %, P<0.01). The relative FIQ of these 
patients did not differ from each other (data not shown). Moreover, even 
though the following symptoms: non-restful sleep, diarrhea, dry eyes, 
muscle spasms, tension headache and gastroesophageal reflux disease, 
did not reach a level of significance, they were better represented in 
patients with thyroid antibodies with respect to the other patients. Non-
significant correlations were found between thyroid autoimmunity and the 
age of patients, or with FIQ total scores. The number of post-menopausal 
patients was higher in the group with positive AbTg (66% vs 42.5%, 
P<0.05). Post-menopausal patients had higher FIQ total scores with 
respect to pre-menopausal patients (62.20% vs 51.80%, P=0.005).  
Previous studies have similarly demonstrated that in FM patients there 
were no alterations in the basal levels of T3, T4 and TSH98, while thyroid 
autoimmunity was associated with FM92, with TgAb and TPOAb levels, 
similar to our results. 
It is known that the incidence of depression is increased in subjects with 
FM 99 ; in addition, an association between thyroid antibodies and 
depression has been demonstrate. In our study, most of the FM patients 
suffered from depression and anxiety disorders but we did not find any 
association between depression or anxiety and thyroid autoimmunity as 
other authors found92. Post-menopausal status, independently of age, 
seems to worsen fibromyalgic symptoms, as demonstrated by the higher 
FIQ total scores exhibited by the FM patients studied.  
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A variety of rheumatic manifestations have been described in 
association with autoimmune thyroiditis, such as Sjögren’s syndrome, 
rheumatoid arthritis, systemic lupus erythematosus or scleroderma100. In 
this respect, the authors hypothesized a role of autoantibodies 
characteristic of autoimmune thyroiditis, a possible overlap between 
autoimmune thyroiditis and some autoimmune rheumatic diseases, or a 
systemic inflammatory reaction associated with thyroiditis. In our study, 
FM patients showed a percentage of thyroid antibodies similar to that 
reported for the above-mentioned rheumatic diseases, but FM, unlike 
those pathologies, is not an autoimmune rheumatic disease.  
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Tab. 8. Clinical characteristics of patients and controls. Patients wereseparated according 
to the presence of thyroid autoantibodies. Values are expressed in percentages. 
(significant *Chi quadro test, p<0.01). 
  
All FM 
patients 
N=120 
Patients with 
thyroid 
autoantibodies 
(a) N=50 
Patients without thyroid 
autoantibodies 
(b) N=70 
Controls 
N=30 
Fatigue  81.4 86.0 78.4 23.3 
Nonrestful sleep  66.4 72.0 59.7 23.3 
Anxiety 62.3 64.0 60.3 30 
Depression 38.1 40.8 34.3 3.3 
Irritable bowel syndrome 48.4 52.0 45.9 30 
Constipation 39.0 41.0 40.0 6.7 
Diarrhea 14.4 20.4 8.6 3.3 
Fingers turn blue/white in the cold  21.1 20.0 21.9 
 
20 
Paresthesiae 57.4 62.0 54.8 3.3 
Articular stiffness  70.7 74.0 68.5 20 
Muscular stiffness  66.7 72.0 64.4 0 
Dry eyes1 45.2 56.0 36.5 0 
Dry mouth 44.3 52.0 39.2 6.6 
TMD§ 47.6 52.0 45.9 6.7 
Muscle spasms 49.2 56.0 44.6 6.7 
Tension headache  50.8 60 44.6 16.7 
Allergy 28.7 29.2 29.7 33.3 
Low back pain 57.2 60.0 55.4 23.3 
Restless leg syndrome  48.4 52.0 43.2 6.7 
Gastroesophageal reflux disease  46.8 54.0 40.5 
 
16.7 
Burning/pain with urination 2  21.7 36.0 10.0 
 
10 
Dizziness 38.2 32.6 43.2 6.7 
Allodynia3 49.6 73.5 32.4 0 
Traumatic event 36.6 44.9 31.1 0 
Blurred vision4 33.3 48.9 22.5 3.3 
Sore throat 5 27.7 43.7 16.9 10 
 
(§TMD: Temporomandibular disorders) 
 
1
 Dry eyes: a vs b, p<0.05 
2
 Burning/pain with urination: a vs b, P<0.01 
3
 Allodynia: a vs b, P<0.01 
4
 Blurred vision: a vs b, P<0.01  
5
 Sore throat: a vs b , P<0.01  
 
 
Our results suggest a relationship between thyroid autoimmunity and FM 
and highlight the association between thyroid autoimmunity and some 
typical symptoms such as non-restful sleep, diarrhea, dry eyes, muscle 
spasms, tension headache and gastroesophageal reflux disease. However, 
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only burning/pain with urination, allodynia, sore throat, blurred vision and 
dry eyes had such a high incidence as to be statistically significant. We 
wonder what kind of link there might be between these symptoms and 
thyroid autoimmunity. Burning/pain with urination may be linked to cystitis. 
Cystitis, (in particular interstitial cystitis, IC) and fibromyalgia have a 
significant overlap in symptomatology, because both display diffusely 
increased peripheral nociception101. Besides, many patients with systemic 
lupus erythematosus, Sjögren’s syndrome and fibromyalgia syndrome 
show antibodies against urothelium and/or muscle cells and/or other 
connective tissue components of the urinary bladder96. So far, there have 
been no published data regarding an association between thyroid 
autoimmunity and IC.  
Allodynia, meaning "other pain", is an exaggerated response to otherwise 
non-noxious stimuli and can be either static or mechanical. It is reported 
that pain distribution in FM is associated with hypothyroidism and it has 
been seen that the intracellular fT3 level is inversely correlated with the 
pressure-pain threshold102. Plasmatic fT3 levels in our FM patients were in 
the normal range, but the higher presence of hyperaesthesia allowed us to 
hypothesize an alteration of the plasma membrane transport of T3, 
resulting in low intracellular concentrations of T3103. 
Sore throat, blurred vision and dry eyes are symptoms that may be related 
to a subclinical thyroid disease.  
Although our FM patients with thyroid autoimmunity showed a higher 
incidence of the above-mentioned symptoms, their FIQ scores and TPs 
 33 
did not differ from the euthyroid FM subjects, and this is probably due to 
the more detailed and different (from those of FIQ) questions put to them. 
Also, other authors did not find any differences in the FIQ scores between 
FM patients with or without thyroid autoimmunity91. 
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Fibromyalgia and Anti-Polimer Antibodies 
Researchers have suggested that many of the symptoms reported by 
women with silicone gel filled breast implants appear to be similar to those 
observed in patients with FM104. Tenenbaum and colleagues105 reported 
that many silicone breast implant recipients produced serum antibodies 
that recognized what initially appeared to be a high-molecular-weight 
antigen. After further characterization, it was determined that this antigen 
was not a protein, but a complex composed of partially polymerized 
acrylamide. Because of the polymer nature of the antigen, these 
antibodies have been named antipolymer antibodies (APAs). Because of 
the suggested similarities between FM and reported symptoms by patients 
with silicone gel-filled breast implants, one of us examined the association 
of APA and FM and found that 47% of patients in a general 
rheumatological setting in the United States were seropositive for the 
presence of APA106. Consequently, other researchers began to investigate 
the APA seroactivity in patients with FM, finding controversial data107,108. 
In light of these results, we examined the APA levels in a cohort of Italian 
FM patients and investigated their association with disease severity and 
cytokine levels. To determine whether APA results from a generalized 
autoimmune response, the APA seroreactivity was evaluated also in 
several autoimmune disease noncase groups including rheumatoid 
arthritis, Sjögren's syndrome, systemic sclerosis, systemic lupus 
erythematosus and undifferentiated connective-tissue disease. 
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We recruited 285 consecutive patients (270 females, 15 males) 
affected by primary FM2, 40 noncase individuals (16 rheumatoid arthritis 
cases, two Sjögren's syndrome cases, 16 systemic lupus erythematosus 
cases, four systemic sclerosis cases, two undifferentiated connective-
tissue disease cases) and 100 healthy age-matched and sex-matched 
subjects. Individuals with a history of silicone gelfilled breast implants or 
breast surgery were excluded from the study. Written consent was 
obtained from all participants after a full explanation of the procedure. For 
each patient the tenderness at tender points was evaluated by means of 
the Fischer dolorimeter48. To estimate the impact of FM on the quality of 
life, all patients and control individuals received a Fibromyalgia Impact 
Questionnaire49. All patients were asked whether they had frequently 
suffered any of the following symptoms in the past 12 months: tiredness, 
sleep disturbance, anxiety, depression, irritable bowel syndrome, 
constipation, diarrhoea, Raynaud's phenomenon, paresthesiae, articular 
stiffness, muscular stiffness, dry eyes, dry mouth, temporomandibular 
disorders, tension headache, allergy, low back pain, restless leg syndrome, 
gastroesophageal reflux disease, burning/pain with urination, dizziness, 
allodynia, traumatic event, blurred vision and sore throat. 
We arbitrarily classified the FM severity on the basis of the tender point 
count: the presence of 11 tender points was considered mild severity, the 
presence of 14–16 tender points as moderate and the presence of more 
than 16 tender points was designated severe. 
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APA levels were determined on serum samples by an indirect ELISA 
kit that detects IgG APA (Corgenix, Westminster, CO, USA), according to 
the manufacturer's instructions. Cytokines (IL-1, IL-6, IL-8, IL-10 and 
TNFα) were measured by ELISA in plasma (Bender MedSystem, Austria, 
Vienna). 
Demographic and clinical data of the 285 FM patients are presented in 
Table 9 
 
Tab 9. Demographic, clinical characteristics and APA levels of 285 FM patients. Results 
are expressed as mean ± SEM. 
 All FM patients 
Patients with      
APA >30 U 
Patients with      
APA <30 U 
Gender 270 F; 15 M 57 F; 3 M 213 F; 12 M 
Age (years) median 
(range) 
54 (19 – 82) 46 (19 – 74) 56 (20 – 82) 
TP  14.29 ± 0.29 13.88 ± 0.83 14.30 ± 0.34 
TPi  2.17 ± 0.04 2.17 ± 0.12 2.19 ± 0.04 
Onset disease  9.19 ±  0.60 8.77 ± 1.19 10.11 ± 0.67 
FIQ  58.21 ± 1.22 55.89 ± 2.59 58.46 ± 1.39 
Tiredness  6.96 ± 0.17 7.16 ± 0.41 6.88 ± 0.19 
Pain  6.80± 0.17 6.31 ± 0.42 6.87 ± 0.18 
Tender Point Index (TPi) was calculated as the sum of each positive TP score divided by 
the total number of TP. 
 
 
 
There are no significant differences between the FM subset with 
positive APA and those FM patients with negative APA. The serum APA 
level (mean ± standard error of the mean) was 22.45 ± 2.55 U in the FM 
patients and was 19.93 ± 3.74 U in the control individuals (Figure 2). 
Considering a cut-off value of 30 U, APA positive values were detected in 
60 FM patients (21.05%) and in 15 healthy control individuals (15.00%) 
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without significant differences in seropositivity among them. Patients with 
moderate (19.17 ± 4.44) and severe symptoms (25.05 ± 4.42) had slightly 
higher APA levels with respect to patients with mild symptoms (13.18 ± 
2.01) (Figure 2). No correlations were found between the APA levels of 
FM patients and the onset of the disease, the tender point counts or 
scores, or pain. A negative correlation between APA levels and age was 
found both in FM patients (P < 0.0001) and in control individuals (P= 
0.0294). 
 
 
Fig. 2. (A) Serum levels of APA antibody in FM patients and in controls. (B) Fibromyalgic 
patients were separated according to symptoms severity. Patients with moderate and 
severe symptoms had slightly higher APA levels with respect to patients with mild 
symptoms (P=0.08). 
 
 
 
 
 
 
 
 
 
Considering the subset of FM patients with positive APA, significant 
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Impact Questionnaire (P = 0.042) and between APA levels versus 
tiredness (P = 0.003). Patients with positive APA levels showed a lower 
percentage of constipation (26% versus 42%, P < 0.05) and a higher 
percentage of sore throat (43.5% versus 24.4%, P < 0.05). 
No differences in cytokine levels were detected between FM patients with 
mild, moderate or severe symptoms or between those FM patients with 
APA-positive/negative values. A significant correlation was found, however, 
between APA levels and IL-1 values within the subset of patients with 
positive APA (P = 0.0072; Figure 3). APA seroreactivity results were low 
(7.7%) in the autoimmune noncase group. 
 
 
Fig. 3. The sub-group of FM patients with APA >30 U (N=60), showed positive correlation 
between APA and IL-1 value (P=0.0072; r=0.379). 
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The production of APA antibodies may result from an immunological 
response to self-antigens or to environmental agents, such as medications, 
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silicone, or other chemicals, which results in the formation of antibodies 
cross-reacting with partially polymerized acrylamide. Because it has been 
shown that APA antibodies are present in about 50% of patients with 
silicone breast implants, and the highest prevalence of APA is found in 
implant patients with severe symptoms of a FM-like syndrome100, subjects 
with a history of silicone gel-filled breast implants or breast surgery were 
excluded from the present study. Our objective was to examine the 
presence of APA seropositivity in 285 nonimplanted FM patients and to 
verify whether APA levels correlate with disease severity and with cytokine 
levels. We did not find differences of seropositivity between FM patients 
and control individuals but did observe that patients with moderate and 
severe symptoms exhibited qualitatively higher levels of APA, even if not 
statistically significant, with respect to patients with mild symptoms. Lee 
and colleagues103 also did not find differences between Korean FM 
patients and control individuals, but reported a lower percentage of 
seropositivity (7.2%). Wilson and colleagues101, on the contrary, studying 
an American population, found a higher percentage of seropositivity in FM 
patients (47%) while the percentage reported for control individuals was 
similar to ours. Wilson and colleagues101, like the present study, observed 
higher APA levels with the presence of more severe symptoms, while 
other authors showed a downward trend as the symptom severity 
increased. Interestingly, in our study the APA levels correlated with 
Fibromyalgia Impact Questionnaire estimates and tiredness results in the 
subset of seropositive patients, so APA correlated with the severity of the 
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disease only when it is positive. This is the first study reporting an 
association between APA seropositivity and the Fibromyalgia Impact 
Questionnaire. Like other reports102,103, we found that the APA assay was 
negatively associated with age, probably because APA is not associated 
with autoimmune diseases and with a T-helper-2 response. We found a 
positive correlation between APA and IL-1 levels in the patient subgroup 
with APA >30 U, which might be associated with an immunological 
response to environmental agents in some way related to polymerized 
acrylamide. The higher percentage of sore throat in the seropositive 
patients might in some way be linked to this response. This possible 
association is further strengthened by previous observations of elevated 
levels of APA in patients with infection- associated malfunctions of 
silicone-based ventriculoperitoneal shunts109. 
We found a low prevalence of APA seroactivity in the noncase group that 
is about one-half of that found in FM patients. This result is in accordance 
with a precedent work100, re-emphasizing the thesis that APA is not a 
general marker for autoimmune disease process. 
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ATP, Calcium and Magnesium in Fibromyalgia 
The great interest in investigating the biological features of FM is 
principally due to the severe discomfort of patients and high incidence in 
worldwide population (0.5–5%), especially females110 [3-7]. Fibromyalgia 
syndrome has been related to disturbances of hypothalamic-pituitary axis 
together neurotransmission imbalance, involving excitatory amino acids, 
catecholamines, substance P and serotonin (5-HT)111: patient’s symptoms 
may derive from poor stressor modulation, sensitisation of specific 
nociceptor neurons and pain threshold diminution in response to multiple 
environmental factors, such as mechanical or emotional trauma, chronic 
stress and infections. In particular, the role of 5-HT has attracted much 
attention: serum 5-HT79or cerebrospinal fluid levels of the 5-HT precursor 
tryptophan have been found decreased in FM. In parallel to 
neuroendocrine studies, also tissue ultrastructural analyses have been 
carried out in affected subjects: electron microscopy has revealed 
disorganized fibers and actin filaments, altered mitochondria, defects in 
capillary microcirculation, glycogen and lipid accumulation together DNA 
fragmentation in muscle biopsies of FM patients112,113.  
Moreover, the use of  31P magnetic resonance spectroscopy has 
allowed the analysis of biochemical substrates in the fibromyalgic muscle: 
higher concentrations of phosphodiesterase (PDE) products and inorganic 
phosphate (Pi) have been observed in patients in comparison to controls114, 
together a decrease in phosphocreatine, ATP and phosphocreatine/inositol 
phosphate (IP) ratio in the quadriceps115, confirming previous results of 
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reduced ATP, ADP, phosphocreatine and increased AMP and creatine in 
trapezius biopsies116. Some researchers have also measured metals like 
calcium and magnesium in FM subjects. These two cations, in fact, 
compete each other in modulating muscle contraction as well as in 
regulating many enzymatic reactions involved in energy metabolism, signal 
transduction and brain activity. Results concerning levels of calcium and 
magnesium in FMs are to some extent controversial: some authors 
observed reduced serum calcium and calcitonin levels in a small sample of 
FM patients98, while others report a normal range of plasma calcium and 
magnesium levels in patients affected by FMs together their reduced 
concentrations inside polymorphonuclear leukocytes117. 
In the search of cellular substrates that can relay CNS axis and muscle 
energy alterations in FM patients, easily available blood platelets represent 
an helpful and simple peripheral model. Platelets possess mitochondria, 
the entire pool of enzymes or proteins involved in oxidative energy 
production and, consequently, they are active in ATP turnover. Moreover, 
platelets are activated during the inflammation response and several 
neurochemical sites, such as monoamine receptors and transporters, are 
located on their plasma membrane 118 , enabling the study of either 
neurochemistry or ATP energy metabolism in FM. Some recent studies 
carried out in our laboratory have shown a significant increase of platelet 
peripheral benzodiazepine receptor (PBR) (now named traslocator protein, 
TSPO11,) together high plasma levels of the proinflammatory chemokine 
interleukine 8 (IL-8), low serum cortisol11 as well as a reduced density and 
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functionality of the platelet 5-HT transporter (SERT)12 in FM patients. As a 
consequent step, we decided to pursue the search by comparing ATP, 
calcium and magnesium levels inside platelets obtained from a group of 
FM patients enrolled at our Department and in a group of sex-age matched 
healthy volunteers, where TSPO and SERT equilibrium-binding 
parameters were again measured.  
For this study we enrolled twenty-five consecutive patients affected 
by primary FMs (FM, 24 females and 1 male), aged 48.8 ± 9.3 (mean ± 
SD) and 25 age sex and age matched healthy volunteer (HC) took part in 
the study. The diagnosis of FMs was assessed by the ACR criteria2. 
 The admission criteria comprised a negative history for major 
psychiatric illnesses or neurological disorders. Comorbidity with psychiatric 
disorders was evaluated by means of the Structural Clinical Interview for 
DSM IV axis-I disorder (SCID-I/P)68. None of subjects was suffering from 
any major physical illness, as assessed by medical examination and 
routine blood or urine tests. Patients or control subjects followed their 
usual diet or physical activity and were free of any kind of medications, 
including benzodiazepines or other psychoactive drugs at the moment of 
withdraw. Patients underwent a wash-out period of two months for aspirin, 
phosphodiesterase inhibitors, calcium channel blockers, sulfur or 
magnesium integrators or nonsteroidal anti-inflammatory drugs.  
Each patient was evaluated for tenderness at TPs by means of the 
Fischer dolorimeter49. Either patients or controls received a “Fibromyalgia 
Impact Questionnaire” (FIQ)48  
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Table 10 resumes all patient characteristics as well as FM clinical 
scores at the moment of blood sampling. In control subjects, TP gave a 
much lower mean score than patients, never satisfying the FM diagnostic 
criteria, similarly to the FIQ, pain severity and tiredness indexes (data not 
shown).  
 
 
 
 
Table 10 Clinical characteristics of the 25 FM patients joined in the study.  
Results are mean ± SD; FIQ: Fibromyalgia Impact Questionnaire; FM: 
fibromyalgia; TPi: Tender Point index.   
 
The method used for the measure of intracellular ATP levels is based 
upon the induction of ATP release from cytoplasm towards the 
extracellular compartment. ATP was released from platelet suspension 
 Patients with FM         Ref. range 
Characteristics:    
Tender points:                                                           16 ± 3.6    0-18 
FIQ: 
    57.9 ± 17.3             0-100 
Tiredness: 
  6.95 ± 2.5          0-10 
Pain 
     7.35 ± 2.4              0-10 
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using an Adenosine 5’-Triphosphate Bioluminescent Somatic Cell Assay 
Kit which follows the luciferin-luciferase reaction.  
 
Sample platelet ATP amount (ATPs) was calculated by the equation:  
 
                     
                    
Where ATPstd was the ATP known concentration (in moles), added as 
internal standard, I.S.; L(s) was the light emitted by “blank” sample without 
I.S., and L(s +std) was the light emitted by sample containing I.S. 
The  [Ca2+]i was determined using the long wavelength indicator fluo3-
AM and [Mg2+]i by means of the fluorescent probe mag-fluo4-AM. Platelets 
were incubated with 2µM fluo3-AM or mag-fluo4-AM, with the addition of 
100µM aspirin, 0.02% Pluronic F-127 to enable the good dispersion of 
hydrophobic AM esters in aqueous media and 2.5mM probenecid to 
prevent dye leakage.  
Intracellular ion concentration, expressed as nM for [Ca2+]i, and mM for 
[Mg2+]i, was determined by the equations: 
(F3-F3min) [Ca2+] = (F3max-F3) 
x Kd(nM),Ca2+ 
 
(F4-F4min) [Mg2+] = (F4max-F4) 
x Kd(nM),Mg2+ 
(ATPstd.) x  (Ls.) ATPs =          L(s.+std.) – L(s.) 
 46 
where  Kd was each cation dissociation constant in our experimental 
conditions.  
As shown in Fig. 4, ATP intracellular levels were markedly lower in 
patients affected by FMs as regards to those obtained in healthy 
volunteers (P<0.0001). The analysis of platelet calcium and magnesium 
concentrations is depicted in Fig. 5: a trend toward higher [Ca2+]i mean 
values was observed in patients without reaching the statistical 
significance (P=0.063), whereas [Mg2+]i values were significantly increased 
in FM patients (P=0.022). Spearman correlation analysis between ATP 
levels as function of [Ca2+]i  and [Mg2+]i levels were not significant (P>0.05) 
as well as those as function of clinical assessment (data not shown).  
 
Figure 4: Platelet intracellular ATP levels. The figure presents the bar histograms of 
ATP concentrations (fmol/plt) inside platelets of healthy controls (n=25, HC) and FM 
subjects (n=25, FM). 
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Figure 5: Platelet intracellular [Ca2+ ], nM  (A) and [Mg2+ ], mM  (B).  Divalent cation 
intracellular concentrations were measured in platelets from healthy controls (n=25, HC) 
and subjects affected with FM (n=25, FM). 
 
With the present work, we 
propose a disturbance in platelet ATP-nucleotide metabolism-signaling as 
a possible biochemical feature of FM disorder.  Since ATP is a key 
molecule converging multiple metabolic pathways and functions inside 
cells, its decrease, as observed in FM patients, can result from many 
interrelated mechanisms. Primarily, a reduction of intracellular ATP levels, 
the final product of glucose catabolism, suggests an imbalance between 
ATP synthesis-consumption inside platelets of FM subjects. Perturbations 
of glucose metabolism have been previously detected in patients affected 
by FMs: reduced serum levels of growth hormone (GH), lactate 
dehydrogenase (LDH) muscular iso-enzyme 4 (H1M3), decreased 
concentrations of ATP inside erythrocytes and hyperpyruvicemia 119 , 
together increased levels of insulin 120 have been observed in 
normoglycemic patients as regards to controls. Reciprocally, FM 
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symptoms have been found in association to metabolic syndrome in 
women121. Moreover, there are some evidences that sleep could contribute 
to ATP metabolic changes: a correlation between sleep loss and variations 
in the secretion of metabolism hormones has been found among healthy 
volunteers122. Therefore, non-restorative sleep symptoms in patients with 
FMs could provoke metabolism troubles. Disturbances in ATP metabolism 
can be also linked to altered stress-dependent hormonal responses, like 
the hypothalamic-pituitary-adrenal (HPA) axis and glucocorticoid secretion 
in FMs123. In addition, beside its role as the main chemical energy donor 
for cell unfavorable reactions and functions, ATP is part of the adenosine 
phosphorylation pathway (adenosine-AMP-ADP-ATP) and it can be 
released outside cells interacting with specific ionotropic or metabotropic 
receptor subtypes, the purinergic receptors. The functions of ATP 
“signaling” are intriguing123 but not surprising, if one considers that the 
manage of extra-intracellular contents in small biomolecules, like 
nucleotides, has been one of the first biochemical necessity during 
evolution, being strongly related to the “discrimination” among stressors, 
xenobiotics and endogenous metabolites, therefore to the metabolic 
response to external changes. Interestingly, purinergic receptors have 
been involved in stress, pain and nociception124 and their cross-talk with 
adenosine receptors 125  or modulation by ectoATP nucleotidases123 is 
actually a topic of upward interest in clinical research. In addition, it should 
be mentioned that the adenosine-ATP system relays both catecholamine 
and sulfur metabolism, via sulfotransferase and N-methyl transferase 
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activities. The present ATP reduction observed in our group of FM patients 
may also be related to changes in platelets [Ca2+]i or [Mg2+]i levels: we 
found herein a trend toward higher [Ca2+]i  concentrations in the presence 
of a little but significant [Mg2+]i increase in patient platelets, in comparison 
to controls. Like ATP, these two cations have a basic relevance for cell 
physiology. In a previous work, [Ca2+]i and [Mg2+]i have been found 
reduced in polymorphonuclear cells of patients with FMs117. A possible 
explanation to this contradiction could be that diverse adaptive 
mechanisms and dynamics for controlling Mg2+ and Ca2+ levels exist 
among the different blood differentiation cell lines and/or that different 
methodologies were used. Thus, these results may define, more generally, 
a diminished homeostatic capacity in affected subjects to regulate ATP, 
Ca2+ and Mg2+ cell pathways/fluxes within or outside cells, also suggesting 
that an enhancement of ATP-dependent Ca2+/Mg2+ pump activities may 
have contributed to the cytoplasm ATP depletion observed herein. In fact, 
the absence of a significant correlation of platelet ATP content vs. [Ca2+]i 
and [Mg2+]i  implies that other factors also brought about these results.  
Speculatively, the increased levels of Mg2+, considered an antagonist of 
Ca2+, may represent a compensatory attempt to restrain Ca2+-dependent 
enzyme activities inside platelets of FM patients: in fact, [Ca2+]i is under 
striking control within cells, owing to the high potency of this cation to 
enhance many cell “cascade” responses. We can suppose that subjects 
with a diagnosis of FMs have a scarce muscle fiber capacity to repair due 
to altered monoamine transmission and hormonal changes 126 , in turn 
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provoking a reduced homeostasis of ATP, Mg2+ and Ca2+ cell 
concentrations.  
An important aspect that need further investigation in FM patients is 
represented by the study of signal transduction mechanisms: as a matter 
of fact, ATP is the substrate of the membrane-bound enzyme adenylyl 
cyclase (AC), stimulated or inhibited by Gs/Gi protein coupling receptors 
(GPCRs), which operate in the cyclic AMP (cAMP) signal transduction 
cascade. For instance, some authors 127  have observed a reduced Gi 
protein functionality together increased cAMP levels in lymphocytes of FM 
patients, giving additional support to the presence in this syndrome of 
abnormalities in either ATP-dependent pathways or immune response 
dysfunctions. The phospholipase C pathway, activated by agonists of the 
Gq-linked GPCRs should be concomitantly investigated: this pathway is 
able to raise [Ca2+]i via inositol tri-tetraphosphate IP3/IP4 together the 
diacylglycerol (DAG)-dependent enhancement of protein kinase C activity 
which has been linked to SERT regulation128. It appears quite significant 
that either SERT or TSPO number have been found reduced or increased, 
respectively, in this group of FM patients (data not shown) as previously 
observed by our research group11,12. As a consequence, we consider a 
good proposal checking the relative balance between ATP and 
phospholipid signaling in persons with FMs.  However, in contrast to 
results of TSPO and SERT in FM patients11,12, we were not able to find a 
significant correlation between clinical scores and platelet ATP levels or 
[Ca2+]i-[Mg2+]i (data not shown). We suggest therefore to extend the 
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number of subjects concurrently evaluated for SERT, TSPO, ATP, [Mg2+]i 
and [Ca2+]i  platelet parameters, by estimating specific symptom profiles or 
“spectra”.  
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Quality of life in fibromyalgia  
As in other chronic disabling conditions, and with respect to the 
musculoskeletal disorders, FM can affect work capacity, family life, social 
commitments, and quality of life 129 . According to the World Health 
Organization definition, Health-Related Quality of Life (HRQoL) refers to 
the emotional, physical and social aspects of the daily experience that are 
influenced by a disease and/or its treatment130 [10]. FM has been shown 
to have a more severe impact on all aspects of HRQoL and to cause more 
severe disability in daily living activities than other rheumatic conditions 
involving axial skeleton131 or than chronic regional pain syndromes132.  
In this study, we evaluated the HRQoL in a 117 FM patients using the 
Medical Outcomes Study 36-item Short-Form Health Survey (MOS-SF-
36)133, a reliable, valid, and responsive self-report instrument widely used 
in musculoskeletal disorders. We expected that the presence of lifetime 
psychiatric comorbidity would predict additional impairment for this 
outcome measure. 
Lifetime psychiatric diagnosis were carried out by residents in psychiatry 
with at least 3 years of clinical experience using the Structured Clinical 
Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P). The MOS 
SF-36 was used to assess general health status. It consists of 36 items, 
35 of which are aggregated into 8 multi-item scales that measure: Physical 
Functioning (PF, extent to which health limits physical activities); Role 
Physical (RP, extent to which physical health interferes with work or other 
daily activities); Bodily Pain (BP, intensity of pain and effect on normal 
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work); General Health (GH, personal evaluation of health, current and 
outlook): Vitality (VT, feeling energetic), Social Functioning (SF, extent to 
which physical health or emotional problems interfere with normal social 
activities); Role Emotional (RE, extent to which emotional problems 
interfere with work or other daily activities), and Mental Health (MH, 
general mental health, including depression, anxiety, behavioral and 
emotional control, general positive affect). Briefly, the first four domains 
are related to physical health; the others to mental health. Subscale raw 
scores are standardized and range from 0 to 100, where 0 is the worst and 
100 the best possible health status. The MOS-SF36 scale scores of our 
sample were compared with normative values of the Italian population and 
with a population of patients with diabetes. Each domain of the MOS SF-
36 was coded high or low whether above or below the Italian norm, 
respectively134 [25]. 
No significant differences among the groups in terms of all demographic 
characteristics were found. FM patients scored significantly lower (p<.001) 
on all domains of MOS SF-36 in comparison to the Italian norm. When 
compared with diabetes patients, they resulted significantly impaired on all 
MOS SF-36 parameters except for Role Emotional and Mental Health 
domains: however, in these two areas, FM subjects showed lower scores 
even if at a not statistically significant level (53.8 ± 43.3 vs 57.6, p=.35 and 
52.2 ± 19.8 vs 53.4, p=.51 respectively). 
The prevalence of lifetime psychiatric disorders was 73.5%. The lifetime 
prevalence of major depression (MD) was 50.5%, whereas at least an 
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anxiety disorders was found in 22.2% of the sample (13.6% panic 
disorder; 8.6% generalized anxiety disorder). Moreover, 4.3% of the 
sample suffered from eating disorders. FM patients with psychiatric 
comorbidity were more impaired than those without psychiatric comorbidity 
on all MOS SF-36 domains with statistically significant differences in 
Social Functioning and Mental Health domains (p<.01 and p<.05, 
respectively) (Fig.2). No significant differences between the two groups 
were found concerning demographic and clinical variables that might be 
expected to affect HRQoL, including age, duration of illness and number of 
TPs. 
The specific influence of demographic and clinical variables on each area 
of HRQoL was assessed by fitting 8 multiple regression models, using 
alternatively each of the MOS SF-36 scale scores as dependent variable. 
Age, duration of illness, number of TPs, and lifetime psychiatric 
comorbidity proved to be significant predictors of the patients’ quality of life. 
In this model, age was associated with Role Emotional (B=-2.4, p=.017); 
duration of illness with Vitality (B=-.35, p=.03); number of TPs with Role 
Physical (B=-2.8, p=.018), Bodily Pain (B=-2.4, p=.017) and with General 
Health (B=-2.1, p=.041); lifetime psychiatric comorbidity with Social 
Functioning (B=-12.6, p=.027) and with Mental Health (B=-13.7, p=.001). 
In this study, the HRQoL of 117 FM patients has been assessed by using 
a generic health assessment tool, the MOS SF-36; its validity to evaluate 
the health burden of rheumatic syndromes and their impact on patient’s 
HRQoL has been previously demonstrated [27]. Compared with the 
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normal population, the scores for the eight domains of MOS SF-36 were 
significantly decreased in FM patients. These data are consistent with 
those of previous studies reporting, in FM patients, reduced HRQoL 
values in all SF-36 domains, as compared with healthy control subjects135 
Although FM is characterized by no visible clinical finding, it has a severe 
impact on MH and PF as revealed by the presence of lower MOS SF-36 
mean scores as compared with other chronic disorders, like chronic 
obstructive pulmonary disease and acquired immune deficiency 
syndrome136 , Sjögren syndrome137 , and rheumatoid arthritis138 . In our 
study, FM patients reported significant lower scores than subjects with 
another chronic disease, the diabetes, for all physical domains of MOS 
SF-36 and two of the mental domains of MOS SF-36, such as V and SF. 
The different impact of FM and diabetes on mental health measures might 
be explained by the different degree of other comorbid psychopathological 
conditions, including depression or anxiety. 
In our sample, a high rate of lifetime psychiatric disorders of 73.5%, with 
50.5% suffering from MD, and 22.2% from an anxiety disorder. These 
findings are consistent with previous studies reporting substantial 
psychiatric comorbidity in FM. In a multicenter investigation, lifetime rates 
of 69% and 35% for mood and anxiety disorders, respectively, were 
reported in FM patients. Lifetime comorbid mood, anxiety, and eating 
disorders were recognized significantly more common in subjects with FM 
than in those without FM. The reasons supporting the high prevalence of 
psychiatric disorders among patients with FM require further investigations. 
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Comorbid psychiatric disorders may precede the onset of FM or 
developing as a consequence of having FM. More broadly, a growing body 
of research is consistent with the hypothesis of a shared vulnerability for 
FM and mood and anxiety disorders, as well as for affective spectrum 
disorders. In our study patients with comorbid lifetime psychiatric disorders 
did not differ from subjects without psychiatric comorbidity concerning 
demographic and clinical variables related to FM. This is consistent with 
previous studies reporting that pain intensity and interference were not 
significantly related to psychiatric comorbidity and that anxiety and 
depression were independent of levels of pain in FM subjects. It can be 
argued that psychiatric comorbidity represent a frequent addictive 
condition for patients with FM that may contribute to a significant 
impairment of their well-being and functioning. In line with this hypothesis, 
in our study the presence of lifetime psychiatric disorders was associated 
with a poorer HRQoL in patients with FM. On one hand, as the most part 
of our patients with psychiatric comorbidity were affected by MD, it is 
possible that they might have an affectively-biased cognition which may 
explain the self-reported lower patient’s perception of functioning. On the 
other hand, it has been showed that patients with chronic medical 
conditions and comorbid depression had additive functional impairment; 
depression may further increase psychological dysfunction both in 
psychiatric and medical outpatients and has been linked to an increased 
functional disability, decreased energy, less interest in leisure, lower 
motivation, and problem with interpersonal relationships139. In the present 
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study, the negative impact of lifetime psychiatric disorders on HRQoL was 
confirmed by a regression analysis that showed a significant negative 
correlation with the SF and MH domains of MOS SF-36. These findings 
are consistent with previous observation concerning the negative impact of 
depression and anxiety symptoms on quality of life of FM patients140.  
When interpreting these data, several limitations should be kept in mind. 
A sample restricted to subjects seeking treatment from a tertiary-care 
center may limit the generalizability of these data to the general 
population of subjects with FM. Moreover, certain confounding factors, 
such as severity of other medical comorbidities, diet, exercise, and other 
lifestyle factors, that potentially could affect health status were not taken 
into account. In addition, in our study only a single outcome measure was 
considered; further studies, using multiple measures of HRQoL, as well 
as more objective measures of functioning, are needed. 
 
 
 
 
 
 
 
 
 
 
 58 
Conclusion 
 
The results about PBR concentration and activity suggest that an up-
regulation of PBR occurs in platelets of FM patients and may provide new 
insights into the pathogenesis of FM and form the basis of future studies 
on steroidogenetic involvement of pain-related PBR in this syndrome.  
Moreover the alteration in the rate of SERT which seems to depend not 
only on the SERT number. In fact, Bmax is not correlated with Vmax (data 
not shown). In the patients with FM, the decrease in 5-HT levels, which 
had already been observed, together with the impaired SERT functionality, 
might contribute to the pathogenesis of the disease, both in quantity and 
rate. In fact, these two factors are important because they are correlated 
with the level of disease severity. Thus, the results of the present study 
are in agreement with the hypothesis that a deficit in the 5-HT transporter 
site could be of pathogenetic significance in FM syndrome. 
The data about thyroid dysfunction suggest that thyroid autoimmunity is a 
marker of the severity of FM, especially if patients are in post menopausal 
status, but the pathogenic mechanisms underlying this association still 
remain unknown, and further studies are needed. 
The data on APA remarked that APA  cannot be considered a marker of 
disease in Italian FM patients. Its presence, however, might permit the 
identification of a subset of FM patients with more severe symptoms and 
who may respond differently to different therapeutic strategies. APA 
seroactivity is also not a general marker for autoimmune disease 
processes.  
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The observation of platelet ATP decrease in FM subjects together our 
platelet TSPO increase and SERT reduction, combines loss in cell energy 
status to stress-mood biological correlates, according to an integrated 
multidimensional model of FM pathophysiology.  
In conclusion, our findings open up to multiple hypothesis and future 
studies about FM etiopathogenesis, in theory converging neurotransmitter 
secretion, neuroendocrine function and energy metabolism-signaling. 
Moreover, it seems clear that the clinical and biological follow-up of FM 
patients would help to find new and more standardized treatment 
strategies among patients and to individuate sub-groups of subjects 
needing different therapies, including appropriate cognitive-rehabilitative 
and diet therapies. From genetic research, it emerges that more than one 
gene can contribute to the pathogenesis of this disorder, including 5-HT, 
dopamine and catecholamine systems. Even if the mechanisms of gene 
transmission are not known in FMs, the fact that multiple genes are 
involved in the syndrome could explain the patient heterogeneity in the 
response to different pharmacological tools. For instance, in the treatment 
of FM patient pain, “pure” serotonin agents or “mixed” antidepressants like 
selective serotonin and norepinephrine reuptake inhibitor (SNRI) have 
shown different degree of efficacy. Moreover, psychiatric disorders seem 
to occur at high rates in patients with FM and may contribute to an 
additional impairment of HRQoL. Thus, the clinical evaluation of patients 
with FM should include a routinely careful psychiatric assessment: 
effective diagnosis and treatment of comorbid psychiatric disorders may 
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be helpful to improve the HRQoL of FM patients. Further studies, 
comparing different treatment strategies, are needed to better understand 
the possible benefits of psychopharmacologic or psychotherapic 
interventions on HRQoL and functioning of FM patients. 
However, our data confirmed the hypothesis that Fibromyalgia is a 
multifactorial disease, involving neuroendocrine disturbance, 
neurosensorial dysfunction and neurotransmitters abnormalities, that 
through triggering factor lead to the clinical manifestation.  
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